Top Markets
#1 Islamic Coin Islamic Coin +151.56%
#2 Black Phoenix Black Phoenix +35.83%
#3 Palladium Network Palladium Network +20.31%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.14%
#5 Akedo Akedo +16.13%
#6 Fake World Assets Fake World Assets +12.92%
#7 OpenEden OpenEden +12.68%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.64%
#9 clBTC clBTC +12.01%
#10 Arowana Arowana +11.93%
Coin of the day
Islamic Coin Islamic Coin
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Pozycja w akcjach #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Cena akcji
$0.00366968
Ostatnia synchronizacja: 2024-07-23
Kapitalizacja rynkowa
$291.42K
Zmiana (1 dzień)
-0.81%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Bioasis Technologies Inc. (BTI)

Kategoria

Healthcare
Historia ceny akcji dla Bioasis Technologies Inc. (BTI)
Najwyższa cena zamknięcia: $0.00 dnia 2024-07-01

Najniższa cena zamknięcia: $0.39 dnia 2008-07-01
Historia cen akcji firmy Bioasis Technologies Inc. od 2008 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2024 -39.54%
2023 -92.10%
2022 -64.18%
2021 -13.01%
2020 58.67%
2019 -47.38%
2018 -51.12%
2017 -29.34%
2016 -5.06%
2015 -2.54%
2014 7.46%
2013 -48.22%
2012 185.00%
2011 -7.05%
2010 9.99%
2009 51.29%
2008 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $517.18 32.51%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $857.76 31.47%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $744.96 9.07%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.21%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $259.89 14.81%
BE